Conferencia de resultados del T2 de 2026 de Cellebrite (CLBT): recorte de previsiones mientras el ARR alcanza los 508 millones de dólares

Puntos clave

• Cellebrite cerró el segundo trimestre de 2026 con unos ingresos recurrentes anuales (ARR) de 508 millones de dólares, lo que supone un aumento del 21% interanual, aunque por debajo del límite inferior de su rango de previsiones.
• Los ingresos aumentaron un 16% hasta los 131 millones de dólares. El EBITDA ajustado se situó en 31,8 millones de dólares, lo que representa un margen del 24%.
• La empresa redujo sus previsiones de ARR para todo el año a entre 550 y 560 millones de dólares y su guía de ingresos a entre 555 y 561 millones de dólares, alegando el calendario de los acuerdos, los requisitos de contratación pública y un impulso inferior al esperado de las conversiones de Insights.
• La previsión de EBITDA ajustado para todo el año se elevó a entre 153 y 159 millones de dólares, es decir, un margen del 28%, ya que la dirección mantuvo la disciplina de gasto a pesar de las menores expectativas de crecimiento.
• Shiv Ramji asumió el cargo de consejero delegado con efecto a partir del 13 de agosto de 2026. El consejo de administración describió el nombramiento como una transición planificada y acelerada hacia un liderazgo centrado en el producto y enfocado en plataformas nativas de la nube y la IA.
• La dirección afirmó que no se perdió ningún acuerdo retrasado. Para el momento de la conferencia de resultados, se habían cerrado aproximadamente 4 millones de dólares de operaciones pospuestas, mientras que los ciclos de ventas afectados se alargaron unas seis semanas.

Datos financieros clave

Rendimiento comercial y operativo

América representó el 53% del ARR, EMEA el 34% y APAC el 13%. El ARR creció un 19% en América, un 23% en EMEA y un 29% en APAC.

El crecimiento del sector federal de EE. UU. se aceleró hasta situarse en torno al 15% tras haberse mantenido estable a finales de 2025. El ARR de Defensa e Inteligencia aumentó un 25%, respaldado por la demanda de la plataforma ampliada de Cellebrite.

La adopción de Insights alcanzó casi el 65% de la base instalada a finales del segundo trimestre. Sin embargo, la expansión de precios y de presencia en la conversión se situó por debajo de las expectativas de la dirección, especialmente entre los clientes gubernamentales estatales y locales de EE. UU. El crecimiento en ese segmento se ralentizó desde un rango medio del 20% el año pasado a justo por debajo del 20%.

Los productos de crecimiento generaron el 25% del incremento secuencial del ARR del trimestre, de 15 millones de dólares, frente al 18% del trimestre anterior. Advanced Unlocks, Guardian Investigate y el análisis forense de drones contribuyeron en su primer trimestre completo de disponibilidad.

Cellebrite también cerró su primer acuerdo importante de FedRAMP para Guardian con un cliente federal existente de EE. UU. El contrato multiproducto ascendió a varios millones de dólares, incluida una orden inicial de siete cifras para Guardian.

Genesis generó aproximadamente 400.000 dólares de ARR tras su lanzamiento el 10 de junio y había aumentado a casi 1 millón de dólares para el momento de la conferencia de resultados. Entre sus primeros clientes figuran organismos policiales locales y metropolitanos, fiscales de distrito, instituciones penitenciarias, la fiscalía general de un estado y usuarios corporativos.

Previsiones de la dirección

Las perspectivas revisadas para todo el año asumen que el ARR neto nuevo del segundo semestre se mantendrá a grandes rasgos en línea con el del ejercicio fiscal 2025. Incorporan una expansión más moderada de Insights, una mayor cautela en cuanto al calendario de las transacciones y la eliminación del potencial alcista proveniente de grandes acuerdos con ciclos de ventas más largos y menos predecibles.

La dirección señaló que la perspectiva del EBITDA ajustado absorbe casi tres puntos porcentuales de presión cambiaria por parte del séquel israelí. La empresa también prevé al menos un punto porcentual de mejora en la retención bruta de ingresos para 2026.

Riesgos y aspectos a vigilar

Las grandes transacciones en la nube y de IA involucran a más partes interesadas, revisiones de seguridad y aprobaciones administrativas, lo que dificulta la previsión de sus plazos. Cellebrite se enfrentó a requisitos adicionales vinculados a su condición de entidad extranjera en la contratación pública federal de EE. UU., incluidos permisos para entidades extranjeras.

Las transacciones de la nube en Europa también se enfrentaron a requisitos legales y de auditoría adicionales relativos a la soberanía de los datos, las normas de libertad de información, la anonimización y el acceso del proveedor. La dirección afirmó que posteriormente se cerraron cuatro acuerdos pospuestos en la nube en EMEA.

El volumen de conversión de Insights se mantuvo cercano al nivel del año anterior, pero los clientes adquirieron menos capacidad incremental y aceptaron aumentos de precios más reducidos durante la migración. Esto reduce la aportación al ARR procedente de las oportunidades de conversión restantes.

La dirección reconoció que la cualificación de la cartera de ventas y las previsiones no fueron lo suficientemente rigurosas durante el segundo trimestre. La empresa está aumentando el escrutinio sobre los compromisos de los clientes, los hitos de contratación, el patrocinio ejecutivo y las probabilidades de concretar grandes acuerdos.

Puntos destacados de las preguntas y respuestas con analistas

• Transacciones retrasadas: La dirección señaló que el déficit del segundo trimestre se concentró en cuatro grandes transacciones relacionadas con la nube, incluida una operación de plataforma. No se perdió ninguna oportunidad de negocio, posteriormente se cerraron 4 millones de dólares y los retrasos promediaron aproximadamente seis semanas.
• Contratación pública federal: El proceso de permiso para entidad extranjera añadió de cuatro a cinco semanas a un ciclo de ventas. Desde entonces, Cellebrite ha obtenido un permiso marco destinado a agilizar los pedidos futuros en el departamento correspondiente.
• Aspectos económicos de Insights: La dirección atribuyó el menor impulso en parte a la madurez de las cohortes de clientes posteriores y a un despliegue más amplio de productos heredados. No obstante, afirmó que la retención bruta de ingresos para Insights mejoró en varios puntos porcentuales.
• Adopción de Genesis: Los pedidos iniciales oscilaron entre aproximadamente 6.000 y 10.000 dólares y hasta 200.000 dólares. Su modelo de consumo permite a los clientes ampliar el uso dentro del ciclo presupuestario existente.
• Transición de liderazgo: El consejo de administración afirmó que Ramji había sido perfilado como el eventual sucesor de Tom Hogan y que progresó más rápido de lo previsto. Hogan seguirá prestando apoyo a Ramji y al consejo en calidad de asesor.

Transcripción completa de la conferencia de resultados

Transcripción completa de la conferencia de resultados

Comentarios de la dirección

Operator

Welcome to the Cellebrite Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] I would now like to turn the call over to your first speaker today, Mr. Andrew Kramer. Mr. Kramer, the floor is yours.

Andrew Kramer

Thank you very much, operator, and good morning, everybody. Welcome to Cellebrite's Second Quarter 2026 Financial Results Call. I'm joined this morning by our primary speakers, Adam Clammer, Cellebrite's Chairman of the Board; Shiv Ramji, Cellebrite's new CEO; and David Barter, Cellebrite's CFO. Shiv, Dave and Marcus Jewell, our CRO, will participate on our Q&A session. This call is being recorded, and a replay of the recording will be made available on our website shortly after the call, along with a copy of the transcript.

Please note that today's press release and financial statements, including GAAP to non-GAAP reconciliations are available on the Investor Relations website at investors.cellebrite.com. In addition to the press release, we posted a separate investor presentation that provides an overview of the business and our recent financial performance. I'd like to remind everybody who's listening on the webcast that the slide in your webcast viewer is a placeholder only. There are no actual slides to accompany the prepared remarks. We also published our historical financial information and supplemental data for the first 2 quarters of 2026, each quarter of 2025, along with the full year 2024 and 2023 on our Investor Relations website.

Additionally, unless stated otherwise, our discussion of our second quarter 2026 financial metrics as well as the financial metrics provided in our outlook will be done on a non-GAAP basis only, and all historical comparisons are with the comparable periods of 2025. I'd like to remind you that today's discussion will contain forward-looking statements, including, but not limited to, the company's business operations and financial performance. All forward-looking statements are subject to risks and uncertainties and other factors that could cause matters expressed or implied by those forward-looking statements not to occur.

Actual results could also differ materially from historical results and/or from forecasts. Some of these forward-looking statements are discussed under the heading Risk Factors and elsewhere in the company's annual report on Form 20-F filed with the SEC on March 3, 2026. The company does not undertake to update any forward-looking statements to reflect future events or circumstances. And with all that being said, I'd now like to turn the call over to Adam Clammer.

Adam Clammer

Thank you, Andy, and good morning, everyone. As you saw in this morning's release, our Board has appointed Shiv Ramji as Chief Executive Officer, effective today. Before I go further, I want to take a moment on behalf of the entire Board to thank Tom Hogan. Tom joined Cellebrite 3 years ago as Executive Chairman, and we're incredibly appreciative of his impact. Since taking the reins as CEO last year, we further accelerated our platform strategy, expanded into new markets and adjacencies through both organic development and acquisition and built a stronger foundation that positions this company well for the next chapter. We're very grateful for everything he's contributed and pleased that he'll continue to support Shiv and the Board as an adviser.

I know many of you will ask why Shiv and why now? And this is something the Board has thought about carefully over time. Even after Tom became CEO, the Board recognized that his tenure would likely be limited, and Tom candidly acknowledged that himself. A key priority has been to make sure the right talent was in place around him to carry this company forward, and Tom played an integral role in recruiting much of the current leadership team. When we brought Shiv on board, it was with the clear understanding that he was, for all intents and purposes, positioned to be Tom's successor.

Shiv ramped much faster than we initially expected. The pace at which we need to build and compete is accelerating. And we believe that's best driven by a product-centric leader who is rooted in architecting scalable, cloud-native platforms that can maximize the impact of AI, which is continuing to rapidly scale. We are seeing tangible signs that this represents an enormous opportunity for Cellebrite. And the team was emphatic on the last quarter's call about that. Given this backdrop, we felt it was important to make the change now. Looking ahead, my optimism about Cellebrite's future has not wavered. We have a large and growing healthy market, trusted relationships with virtually every major public sector agency in the democratized world, a differentiated platform and a world-class team that is squarely focused on turning our domain expertise and technology into durable, profitable growth.

And although this year will be choppier than we would otherwise have anticipated, the platform strategy is working. Growth is increasingly coming from our new products outside of extractions and unlocks. We are well positioned to build on our progress given these new initiatives and customer adoption. And with that said, I'll turn it over to Shiv.

Shiven Ramji

Thank you, Adam, and good morning, everyone. Echoing Adam's comments, Tom's partnership over the past several months has meant a great deal to me, and I'm grateful for the foundation he's helped build. Cellebrite continues to make a real consequential impact on public safety around the world, and I see a genuine opportunity to build on that. Because regardless of customer segment, the fundamental challenge is the same. How do you compress the investigative life cycle and rapidly obtain trusted insights and actionable intelligence. Given our core competencies in digital forensics and our intimacy with customers' workflows and our accelerating investments in on-premise capabilities, edge, cloud and AI, Cellebrite is uniquely positioned to turn digital data from any device, any source or environment into actionable, court-approved and mission-ready intelligence.

All of us here are committed to the hard work and disciplined execution required to enhance our platform and expand our business around the globe. I am excited about the opportunity ahead. But today, I want to start with where we are. We did not deliver the ARR and revenue performance we expected in the second quarter. On our last call, we expected a meaningful acceleration in Q2. That acceleration did not materialize at the level we anticipated, and we own that. The immediate shortfall was concentrated in a limited number of large transactions that we expected to close in the quarter, but ultimately moved beyond our anticipated time line. It's worth noting that for some of these transactions, particularly with U.S. federal and European government customers, we encountered new and additional administrative and procurement requirements related to our current foreign entity status.

Additionally, we are also competing for increasingly large and strategic opportunities that now incorporate cloud and AI. These deals involve more stakeholders and in some cases, longer procurement cycles. But I want to be clear, timing is not an excuse. We need to execute these opportunities better, identify risks earlier and forecasted business with greater precision. Another factor impacting performance involves our Insights digital forensic solution. To be clear, we continue to make good progress converting customers to insights, reaching nearly 65% of the installed base by the end of Q2. However, the ARR uplift from pricing and footprint expansion has been lower than we expected, particularly in the U.S. state and local government sector.

So taken together and considering the timing of several product introductions in the second half, we believe the responsible action is to lower our full year ARR and revenue outlook. At the same time, we are raising our full year adjusted EBITDA target, reflecting continued discipline in how we manage the business and prioritize investments. Dave will walk you through the outlook in more detail shortly. The question I want to address next is straightforward. What do we need to do differently? And there are 2 immediate priorities. First, we are raising the standard for sales execution. We have completed a bottoms-up review of our pipeline and our largest opportunities. We're putting greater rigor around qualifying opportunity, customer commitments, procurement milestones, executive sponsorship and cross-functional ownership.

Second, we are tightening our forecasting discipline. Pipeline is not performance. Going forward, we will place greater weight on observable customer actions based on the current environment. And within that construct, we will also more explicitly account for the timing and magnitude of prospective large transactions with major government agencies. None of the disappointment around the quarter or the year changes my conviction in the opportunity in front of Cellebrite. There are a number of positive signs that our strategy to broaden our platform and extend our reach beyond our technical digital forensics user base is, in fact, working.

Our U.S. Federal business had a solid second quarter, and the Defense and Intelligence ARR grew 25%. Our platform is compelling for these customers, and we are now pursuing some of the largest opportunities in the company's history. Our newer offerings are also increasingly contributing to our ARR growth. We saw important adoption of new solutions like Guardian Investigate, Advanced Unlocks and drone forensics in Q2, all of which occurred in their first full quarter of availability. Earlier this week, we secured our first major FedRAMP deal for Guardian with one of our long-standing U.S. federal customers as part of a multiproduct multimillion-dollar deal. This customer placed an initial 7-figure order for Guardian alone that is nearly 35x higher than the average annual spend of roughly $50,000 by an SLG agency on Guardian. Genesis, which launched on June 10, generated more than half a dozen customer wins before the end of the second quarter, and that progress has continued into the third quarter.

We are pleased to see local police departments, major metropolitan agencies, district attorneys and correctional organizations among the early adopters. Just as important, trials have continued to expand into Q3, and we are extending availability beyond the U.S. into the U.K., Australia and Europe. These are all encouraging signals. But I also want to put them in the appropriate context. Innovation, customer interest, pipeline and product adoption only matter if we consistently convert them into ARR, revenue, profitability and ultimately, cash flow. That is the operating discipline we will prioritize moving forward. At the strategic level, the opportunity in front of us is much larger than any specific individual product. Every customer we serve is trying to solve essentially the same problem, compress the investigative life cycle and move from digital evidence to trusted, actionable intelligence faster.

Cellebrite has a unique foundation from which to solve that problem. Deep expertise in digital forensics, extraordinary access to investigative workflows and data and growing capabilities across cloud and AI. Our ambition is to connect those capabilities into a broader investigative intelligence platform that can securely turn digital data from devices, cloud sources and other environments into trusted insights customers can act on. And AI will be an important part of that. We are building a shared Cellebrite AI layer designed specifically for digital investigations, combining forensic context, models and agents with evidence-grade controls around provenance, verification, auditability and human oversight.

The outcome we care about is not AI for its own sake. The payoff is measured in time, quicker time to evidence, accelerated time to insight and ultimately, faster time to action and justice. In the second half, our priorities include enhancing and expanding Genesis. This includes bringing this capability into high security and on-premise environments, and we have already secured an agreement with an anchor customer for an air-gapped offering. We also plan to extend Corellium into additional law enforcement and enterprise vertical use cases and continue advancing our drone forensics capabilities. We will invest aggressively where we see the potential for durable growth, but we will do so with discipline. I'll close with a couple of personal comments and observations.

First, I want to thank all of our Cellebriters who take our mission very seriously and are working hard to deliver on another important quarter. Your energy and efforts are truly appreciated by the leadership team, our customers and our shareholders. In terms of our product and technology organization, Iftach Smith, a seasoned Cellebrite product and engineering executive, will assume leadership on an interim basis until we complete our search for a new leader. Throughout my career, I've been fortunate to build successful technology platforms for businesses that created access, opportunity and better outcomes for people. What drew me to Cellebrite is that the impact here is unusually tangible. Inside every device and within every piece of digital evidence is a human story, a family waiting for answers, a victim seeking justice, an investigator trying to stop the next crime and a nation working to protect its citizens.

For the better part of 20 years, Cellebrite has earned the trust of its customers when the stakes are the highest and involve some of their most consequential missions. That trust is something I take very seriously. This was not the quarter we expected, and we have work to do. As CEO, I accept that responsibility. My commitment to our shareholders is straightforward. We will confront issues early, communicate clearly, allocate resources with discipline and continue earning your confidence by setting realistic yet ambitious goals and achieving them through relentless consistent execution and results. I am confident in the opportunity ahead, and I'm energized by the work required to realize it. With that I will turn it over to Dave, our CFO.

David Barter

Thank you, Shiv. Q2 represented a quarter with some puts and takes. ARR increased 21% to $508 million, but we missed the bottom end of our guidance range. We are committed to executing better, and I believe we will. As I look beyond the execution, it's important to keep in mind that business model transitions are nonlinear. We have made great strides converting our customers to insights. Equally, we are making great strides with regard to cloud and AI. Our business will become stronger and more durable as customers adopt more solutions across our platform. We are also encouraged that our growth products contributed 25% of the $15 million of sequential ARR increase versus 18% last quarter.

Drilling down, our investment in new products continues to reinforce the value of our platform strategy. This was the first full quarter of availability of our Advanced Unlocks and Guardian Investigate Solutions. Each contributed meaningful levels of net new ARR and opened up higher levels of spending. For example, given the volume of evidence stored on Guardian Investigate, combined with its AI capabilities, it's a product that commands increased price versus Guardian Forensics. Another highlight was Genesis, which we launched late in the quarter. The early signs of product market fit are strong. We secured about $400,000 in ARR in the final weeks of June. This product was launched as a consumption product, which provides customers with the flexibility to use as many tokens as they need to compress the investigative life cycle. The initial deals indicate this product will be accretive to our gross profit and P&L.

Let's take a look at ARR by geography. The Americas represented 53% of total ARR. EMEA represented 34% and APAC represented 13%. In terms of growth rates, the Americas grew 19%, EMEA grew 23% and APAC was a standout performer with 29% growth. Looking a bit closer into the Americas, growth in U.S. Federal accelerated into the mid-teens after being flat at the end of 2025. As Shiv noted, the changing dynamic with Insights where customers continue to adopt, but we are not capturing as much price and expansion at the time of conversion was most evident in our U.S. state and local government sales group. Last year, this group delivered growth in the mid-20% range. The growth is now just below 20%.

Fortunately, we are starting to see the benefits of new product introductions. Without those new offerings, state and local government growth would have been in the mid-teens. Turning to revenue. We reported $131 million, up 16% year-over-year. Subscription revenue was $119.5 million, also up 16% and represented 91% of our total revenue. Our Q2 gross profit increased 16% to $112 million, which represents a gross margin of 86%. Second quarter adjusted EBITDA was $31.8 million, a 24% margin. Our profitability continues to be impacted by a challenging FX environment. Headcount was 1,287 employees at the end of June, which is basically flat with the end of fiscal 2025. We reported second quarter operating income of $29.8 million and net income of $29.7 million or $0.11 on a fully diluted basis.

Looking at the balance sheet, we ended the second quarter with $546 million in cash, cash equivalents and investments. For the trailing 12 months, free cash flow was $144.2 million or a 28% margin. Our free cash flow performance reflects the impact of deal structures as well as collections that came in late during the first week of July. As a reminder, our free cash flow last year benefited from a onetime tax refund of approximately $9 million. Overall, we feel good about the underlying free cash flow dynamics and anticipate a stronger overall trend line in the second half of this calendar year. Let's turn to our outlook. We've lowered our full year 2026 ARR guidance range to $550 million to $560 million, a reduction of $15 million at the midpoint.

The change to our second half now assumes net new ARR for the second half of the year that is essentially in line with fiscal 2025. There are several primary factors for this change. The outlook reflects moderation in Insights conversions, specifically the incremental price and expansion at the time of conversion. There is greater prudence in regards to deal timing due to the administrative requirements we discussed earlier that are elongating deal cycles. And finally, we've removed potential upside from larger, more complicated deals where sales cycles are longer and less predictable in the current environment. Our recent FedRAMP win was a great example of this. It required multiple waivers, security reviews and other administrative approvals that, in the end, made it difficult to forecast when exactly this deal would close.

I'd like to take a moment to bridge our updated outlook for 14% to 16% ARR growth with the growth framework we've previously shared. First, we still expect winning new logos and capturing incremental price will generate several percentage points of growth. Second, we now anticipate that Insights will contribute mid-single digits. The third growth driver, Guardian, Pathfinder and Genesis, the cornerstones of our digital investigation and analytics offerings will grow at the lower end of our original expectations in the mid-single digits. We also moderated our expectation for Corellium's contribution to 1 to 2 percentage points. And finally, we remain comfortable about finishing this year with at least 1 point of improvement in our gross revenue retention rate given our performance in the first half.

Given the lower ARR range, we've reduced our full year revenue range to $555 million to $561 million, which represents growth of 17% to 18%. We've raised our adjusted EBITDA targets to $153 million to $159 million, which represents a 28% margin. It's important to highlight this outlook contemplates the business absorbing nearly 3 points of FX headwind from the ILS. We plan to manage our capital allocation thoughtfully while we continue to fund investments critical to durable long-term growth. We remain well positioned to deliver 30% free cash flow margins in 2026 as we move into the seasonally stronger second half of the year. We are increasingly optimistic about our potential to deliver the next step-up in our profitability and free cash flow in 2027 as we demonstrate that we can operate the business without material expansion of the headcount, the FX headwinds subside and new products continue to scale.

Our third quarter expectations are as follows: We anticipate ARR in the range of $524 million to $528 million, representing net new ARR of $16 million to $20 million. We expect third quarter revenue in the range of $145 million to $148 million and adjusted EBITDA in the range of $42 million to $45 million or a margin of 29% to 30%. I'd like to close our prepared remarks by reiterating that reducing our growth expectations is prudent in light of the transitory headwinds we've encountered. We don't take that change to our guide lightly. There is a lot of good happening beneath the headline numbers. Federal is reaccelerating. Defense and intelligence is outgrowing the rest of the company and AI and our Genesis product is off to the strongest start of any product we've ever launched. We remain confident in the long-term opportunity in front of us, and we're focused on executing through the back half of the year to deliver on our updated outlook while setting ourselves up for long-term success. Operator, that concludes our prepared remarks.

Operator

[Operator Instructions] Our first question today comes from Shaul Eyal with TD Cowen.

Preguntas y respuestas

Shaul Eyal

Shiv or David, listening to the call, I wanted to ask what gives you the confidence about the growth potential of the business? And I have a follow-up.

Shiven Ramji

Yes, I'll start. So I think of this year as more of execution reset, not a reset of our long-term growth potential. Like I said, we are seeing good early signals from the work that we're doing in product and also the deal sizes that we are now entertaining. So over the long term, obviously, we are optimistic about the potential of the business, but being prudent about what -- how we execute over the next 2 quarters.

Andrew Kramer

David?

David Barter

Let me offer a little bit of perspective. I mean when you put the quarter in context, we signed and took down orders probably well north of 1,000. In the end, it kind of came down to 4, and it was 4 that crossed the line, and it was 4 that involved cloud. It was one in particular involved a platform. You might recall one of these deals we alluded to last time where they actually called us before we had FedRAMP approval. And even they were a little bit surprised about the change in procurement requirements when you get into cloud and AI and the approvals that we had to secure. And so to be in that spot where a platform order came in, we sold 5 products.

Originally, they were just renewing one product and they bolted on 4 more to it. And so to have a solution like that with a leading agency that's on the vanguard of cloud adoption. I think that's what gives us confidence. I think we've seen cloud transitions and cloud adoption work well in every other part of the economy. There's no reason why it doesn't work well here. The fact that they're adopting cloud, they're adopting AI. And even as Shiv alluded to, we have now customers that are kind of going into on-prem AI, which is a pretty quality -- contemporary and quality business model gives us the encouragement and the confidence.

Shaul Eyal

Understood. As my follow-up, I'm curious with respect to some of the slippage you've seen in EMEA, maybe like in EU countries and some of the administrative requirements you mentioned in your prepared remarks. Can you maybe provide us with more color, maybe slightly elaborate on that?

Marcus Jewell

Sure. It's Marcus. Yes, I'll answer that. So in EMEA, we faced a slightly different challenge, which was based around freedom of information. The growth that we have in EMEA that we wanted in Q2 comes from transitioning major European customers, both in Germany and the U.K. to cloud. That required an extra level of vigor that was not made apparent to us at the start is that as information moves into the cloud from investigations that a new EU law was applied for freedom of information, which meant there was an audit to make sure that any information that we store and process is kept not only in the sovereign location, but equally as a vendor that we are anonymized and we do not get to see that. That was a surprise to both our customers and us, and we had quite a difficult process with legal review to get through that. The good news is we secured 4 of those slip deals already in the quarter, actually all 4 for the cloud, and we now feel confident that we know how to deal with and respond to the CIO's requirements for freedom of information. So that was the explanation for EMEA.

Operator

Our next question comes from Mike Cikos with Needham.

Michael Cikos

On the Defense and Intelligence growth, can you help us by maybe quantifying the magnitude of these elongated sales cycles that you're seeing as well as the conviction you have in the growth from where we sit today over the remainder of the year? And then I just have a quick follow-up.

Marcus Jewell

Sure. So it's Marcus again. Thanks for the question. Great question. So in Defense and Intelligence, actually, delays are less. We actually feel confident about our ability and the nature of those deals, particularly in defense and intelligence continues. The delay that we'll call out was more in the civilian side of the federal business, and that was down to 2 things. The first one was, I have to be honest that the agencies as they move to cloud and AI do not necessarily have the correct procurement tools to understand exactly how to do that. And you're going to see that message portrayed, I think, across a number of vendors. We have a particular additional requirement, which is as a foreign filer, we found that we needed to find other permits, which was new.

Our sponsor is a very high-level CIO in a departmental level, was not even aware of something called an FEP, which is a foreign entity permit requirement, which is applied to cloud technology. Since learning that and learning that process, which created a 4- to 5-week delay, we've managed to secure a master FEP, which means that at a departmental level now, we will be much more expedited in the processing of our orders. So I want to clarify that DNI is not as slowed down as federal agencies, which are using this cloud transition.

Michael Cikos

Thank you, Marcus. And maybe a question here for Adam. I'd just prefer to ask you. If I rewind the clock a year ago, it's when we were saying that Tom was going to be named the CEO. He was the preferred choice. We're now appointing Shiv here effective immediately, which is part of this planned transition you guys are citing. But admittedly, at least from the external side, we didn't have insight to that. So first, can you walk us through like that planned transition? And then secondly, how is the team internally handling that level of change management, if I'm thinking about retaining personnel and just the turnover we're seeing in the CEO seat?

Andrew Kramer

And Mike, it's Andy. I'll just preface that the Q&A, I was pretty explicit that Shiv, Dave and Marcus would lead the Q&A. I don't even know that Adam is connected at this point in time. So I understand -- we understand the question, and we'll endeavor to connect you. But I'll just ask Shiv to provide a little bit of color and perspective there.

Shiven Ramji

Yes. So as Adam had mentioned, this was a planned transition, and both Tom and I have been working on this. And we just accelerated the transition given the opportunity we see with the products and the markets we're operating under. So it just got pushed up much earlier than initially thought.

Adam Clammer

Well, Adam is here, and I'm happy to just echo what Shiv said. This was something that when Tom went in as CEO, which we were excited about and he was excited about, he and we and the Board understood that we would start looking for a product-centric CEO, and it might take some time to find that person and it might take some time to ramp that person so they could assume this position. It happened sooner than we all expected. And it really happened with the full support of the entire management team. So we're delighted that all of the direct reports are excited and supportive about Shiv going forward.

Operator

We'll take our next question from Rudy Kessinger with D.A. Davidson.

Rudy Kessinger

It sounds like in the quarter, there was a number of maybe procurement and permitting and just things of that nature that caught you by surprise. As you look ahead, I guess, have you done a thorough review, I guess, across regions and agencies and governments, et cetera, to ensure that there aren't more surprises potentially that you'll uncover in future quarters? And just any color on why in hindsight, you guys didn't have your arms wrapped around all of these procurement requirements going into the quarter?

Marcus Jewell

Sure. Great question. This is Marcus again. Look, you don't want to be a CRO in a public company with a miss. So first thing, we own that. And of course, if I had known these things upfront, myself and my team, which I believe is an excellent team would have dealt with them. I would say we were in an unprecedented situation as we transition to cloud and AI, where we're having unforeseen things thrown at us. Why we feel confident going forward is we have taken a different approach to the rubric that was face to us to make sure we've applied that logic to our deals going forward and be incredibly rigorous in making sure that the procurement process and understanding the full entity of the procurement process is now completely understood at not only the U.S. government but also an EMEA and APAC level.

We believe with the highest level and working with some of our lobbyists that we now fully understand the mapping of how USG and EMEA is going to apply to us as a foreign filer. And we are now confident that we won't repeat the same issues going forward. And we now have precedent, which is the best thing that we can show evidence to other agencies and other buying entities of how we've been able to transact and met all the requirements that are thrown at us. So what I'm saying is I think we've learned our lesson, but we're also being prudent in our outlook to take in consideration that there could be delays.

Operator

And we'll take our next question from Jeff Van Rhee with Craig-Hallum.

Unknown Analyst

This is Daniel, on for Jeff. Maybe we could just open, Shiv, I'd love to hear a little bit more in terms of your background. And just if you could speak to what attracted you to Cellebrite, the opportunities you see, what's brought you here?

Shiven Ramji

Yes. Thanks, Daniel. Sure. So I mean, for me, this starts with the mission that Cellebrite is focused on. I think what the company has built, the assets that we have is truly impressive. And the mission is really, really important. We play a very, very important consequential role for our customers and their investigation. So I think first was just like the mission is very attractive and very impactful. Then I think of Cellebrite has like really amazing assets. I mean this company is -- we have a hardware component to our business. We have a cloud component now that we've just talked about. AI is now helping us deliver outcomes and capabilities to our initial early adopters, and you can see the customer feedback that we're getting from them.

And then what we can do in DNI is really, really unique and special with, obviously, our hardware offerings and offerings at the edge. So for me, it was just really exciting to see that we have this amazing technology and assets. And if we can weave all of those together to essentially build an autonomous investigative platform that we can continue to grow this company at a pretty significant pace. So I firmly believe in the long-term growth and opportunity, and we're making steady progress towards those. And as we continue to deliver those outcomes and continue to deliver those results, continue to deliver performance from the vision that we have, I think all of you will also come to appreciate what attracted me to this company.

Operator

And our next question will come from Brian Essex with JPMorgan.

Brian Essex

I have 2. One is, I'd love to know a little bit more about the challenges that you saw with Insights conversions and the pricing coming in lower. What percentage of the business does that account for? And if you could just help me understand how those transactions materialized during the quarter? And then the second would be, it seems like things are falling nicely in place for the federal business. You guys acquired Cellebrite Federal a while ago. You got FedRAMP certification. It seems as though the people and the processes are in place for what should be, I think, a pretty good federal quarter. Dave, I'd just let you know how your assumption -- what are your assumptions for business and contribution in 3Q? And what can we expect near term for the federal business? And that's it for me.

David Barter

Thanks, Brian. Great question. As you -- I mean, you're a Pro and you're an expert on the business. So we're driving right now, and I think we kind of indicated that overall between extractions and unlock by the end of the year, that would be about 80%, 81% of total ARR. And I think as you probably recall, in any given quarter when we run the insights, we get a pricing uplift that can be $1 million to $2 million of incremental ARR, maybe even in some forces, a splash more or a splash less. And so what we're really seeing, Brian, as people progress through is ultimately, we got less of that price increase.

And then ultimately, we were just buying in terms of quantity, just at the time of migration, which the migration or conversion were about from a magnitude perspective, almost exactly where we were last year. We were just capturing ultimately a little bit less. And so that really just started to weigh on our view. And I guess I looked at it through the lens of almost every business model transition or migration where at a certain point in time, just the expansion rates start to shift, and we certainly started to see that shift. So that's kind of really what unfolded there, if that's helpful. Brian, do you want me to double click a little more? Is that helpful context? If not, I'll kind of...

Brian Essex

No, super helpful. I appreciate it.

David Barter

And by the way, I mean, one of the other dimensions maybe that's worthwhile is just overall, we did see gross revenue retention continue to climb in the first half. Actually, on Insights, it was up several points. And so I'd say I feel really good about those who have converted and the stickiness of those relationships. I'd say on the federal side, as Marcus and I have looked at the business, I think one of the areas that we did was actually spend more time handicapping. And I'll use that recent FedRAMP win as an example, where it ended up being a nice step-up in terms of net new ARR. But I think we've really handicapped, I'd say, some of the larger transactions knowing the time frame.

And so I'd say we kind of looked at -- this is why I expanded the range as we thought about the outlook to be able to say, fundamentally, we're going to start to contemplate a smaller contribution from any given deal, knowing that these have the ability to be larger cloud and AI deals. And so we just wanted to be a little bit more humble. And so I think when you look at it, and this is why we kind of look at things through the lens of last year with net new ARR being roughly flat year-over-year is that we're kind of counting on the contributions being roughly about the same, little bit more probably in the DNI world than we saw in the SLG world given some of the dynamics that we described. But in aggregate, about flat with what we saw last year. And we think that's a prudent way to look at the business, particularly when we handicap transactions. Marcus, is there anything else you'd add?

Marcus Jewell

Again, we have to take a prudent view of where we are, but we believe that our federal business, as noted, is set up incredibly well. We remain -- 3 things want to remind. We remain with the only FedRAMP high solution for digital forensics available. And the process to get that is a very long and tortuous process. So even though people are announcing they are going for that, it will take an extended amount of time. The second thing is, as you probably know, if you follow the public record markets that the grants are starting to flow. There is the OBB also known as the Biden money, which affects both state and local and federal. And we are confident that we'll see some wash in that business. We also have submitted and actually been shortly for our first ever 9-figure program, and that is in the public market as well. So the leadership team there under Phil and Allan are exceptional, and I feel that they will deliver very good results for us going forward.

Operator

Our next question comes from Bhavin Shah with Deutsche Bank.

Bhavin Shah

David, I just wanted to double-click on Brian's question there just in terms of the outlook you're seeing on the insights migration. Why is it coming in lower than what you might have seen a year ago? Is it just like the most needy customers maybe were migrating earlier and now we're at a point where, hey, it's people that might not need as much of the platform. Is it something competitively that might be changing? Are they using less unlocked? I just wanted to really understand and appreciate kind of what's happening with this customer cohort? And how do you ensure this doesn't happen to the remaining 37% of customers as you kind of go down the path?

David Barter

It's a great question. I think you're certainly seeing with this cohort, you're seeing a little bit more of a conservative posture in terms of how they approached it. And so I think fundamentally, there's a couple of dynamics. One, you're getting to the maturity of the cohorts. And so some of these customers have been buying some of the legacy products over time. And so if you go back in time, the legacy premium or the legacy UFED and so some of them are just, quite frankly, better deployed. And so that's kind of one dimension that's certainly going on.

I think there's another dimension where certainly, as we see the adoption of more products, whether it be the adoption of Guardian or as we saw Genesis starting to go into the base, we are seeing people have the ability to choose more to buy. So there's a few different dynamics that are playing. Again, I'll kind of reinforce GRR is up, GRR for Insights is up several points. And so I think we are when you're starting to climb towards mid-90s on a product level, particularly when people are buying on an annual basis, I think we feel like we have very positive momentum there.

Operator

We'll take our next question from Eric Martinuzzi with Lake Street.

Eric Martinuzzi

I wanted to dive in on the initial deals that you had with Genesis. If you could walk us through the types of customers, these are obviously the early adopters representing that $400,000 worth of ARR that you did book in Q2. Who are those? Is there anything you can kind of categorize those early adopters into? Because I imagine for a lot of your customers, there's an annual budgeting process. And if it wasn't in there at the start of the year, it's going to be hard to sign up for it now.

Marcus Jewell

Great question. So I'll take this one. So it's a broad church. So the good news that we're seeing there is we have secured business at international level for leasing. We have secured business at a state level AG. We have actually secured business in the enterprise. And so what we're seeing is a very broad church and the momentum of conversion is accelerating and the number of trials is accelerating to a great level. We don't see any common use case, which is dominating at the minute. We're actually seeing it because the very nature of an open-ended model with LLM integration allows us to cover pretty much all the markets. So as this develops, we will clearly inform you any hands we see forming. But at the moment, we see it spreading across all of the markets that we exist in.

David Barter

Eric, I might offer just in terms of how you think about the business, we have had some customers go from the pilot and they might start off with, I think the smallest order might be $6,000 or $10,000, and then we've had some customers up towards $200,000. And so now that the business is, as I shared, it wrapped up at about $400,000 and now it's pushing $1 million of ARR. We're starting to see some maturation around how people are adopting, particularly as they've been using the free trial consuming at pretty heavy levels. And as they open up budget and create opportunity, they're biting in some interesting quantities. So again, I think it's overall -- it was nice to see how it monetized over the course of a couple of weeks and 5 or 6 weeks since we closed the quarter, the monetization has continued. And again, we see good activity both in the free trial, but also at the paid level.

Marcus Jewell

I think it's worth adding as our leading consumption product. It gives us the chance to upgrade in cycle extensively. So whereas in state and local and federal, you're normally stuck to your 1-year or your 3-year bid value. Here, what we're seeing the ability to actually do product-led growth as well and upgrade within cycle. So the monetization is much more dynamic than products we've had previously.

Operator

And we'll go next to Jonathan Ho with William Blair.

Jonathan Ho

Can you quantify the size of the pipeline deals lost? And how much is maybe subsequently closed already? And also, I guess one thing I wanted to better understand is how to quantify how much these complicated deals have actually elongated the sales cycle? Like are we talking about multiple quarters here? Just want to understand sort of the dynamics there.

Marcus Jewell

I can give you 3 very good answers here, I think. So the first thing is, the easy one is, no deals are lost. We didn't lose any business throughout this process. Of the business which slipped, as we sit here today, $4 million of that has now closed and booked, which has obviously made our Q2 very different. The elongation is approximately 6 weeks to the sales cycle is what we've seen. So hopefully, that's 3 questions and answers for you...

Operator

[Operator Instructions] And this will conclude today's Q&A portion of the call. I would now like to turn the floor over to Andrew Kramer for additional or closing remarks.

Andrew Kramer

Great. Thank you very much. I'd like to thank everybody for joining on today's call. We look forward to speaking with you in the weeks that follow. We will be at a couple of investor conferences over the next couple of months. Look forward to seeing you there as well. Thank you very much. And until we speak again, have a good day.

Operator

Thank you. This concludes today's Cellebrite Second Quarter 2026 Financial Results Conference Call. Please disconnect your line at this time, and have a wonderful day.